Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

ECB. 2016; 5(6): 259-265


BENEFICIAL EFFECTS OF HYPOTHALAMIC PROLINE-RICH PEPTIDE-1 ON THE HEART FAILURE ASSOCIATED WITH EXPERIMENTAL PANCREATIC NECROSIS AND CRUSH SYNDROME

A. G. Guevorkyan, N. Kh. Alchujyan, H. M. Mikayelyan, V. H. Barseghyan, H. L. Hayrapetyan, H. F. Khachatryan, V.S. Grigoryan, L. H. Melkonyan, S. G. Chailyan, G. A. Kevorkian.




Abstract

Hypothalamic neurosecretory cytokine, proline-rich peptide-1 (PRP-1) may protect against myocardial dysfunction and hypocalcemia
induced by experimental pancreatic necrosis (PN) and/or crush syndrome (CS). 24 and 48 h after initiation of experimental PN, effective
doses of PRP-1 were administered to adult Wistar male rats divided into groups corresponding to early, reparative, chronic, and chronic
recurrent stages of PN. Similarly age and sex matched rats were immediately administered PRP-1 after 2 h of compression injury. The
PRP-1 normalized the histopathological changes in cardiac tissues in the dynamics of both PN and CS. Study of 45Ca++ binding to the
membrane proteins of cardiomyocyte sarcoplasmic reticulum (SR) showed that PRP-1 could prevent an impairment in the calcium binding
ability of the Ca2+ depot proteins caused under pathological conditions. Besides, PRP-1 suppresses a PN and/or CS-induced compensatory
manifestation the affinity to calcium of the 32-kDa SR membrane protein and restores its native properties. The results highlight new
prospects over the functional implications of PRP-1 and its possible therapeutic potential for the treatment of patients at high risk of
cardiovascular disease associated with different pathologies.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.